Marshall Wace, LLP Arcellx, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Arcellx, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 3,300 shares of ACLX stock, worth $178,629. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,300Holding current value
$178,629% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
186Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$213 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$207 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$203 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$166 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$127 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.37B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...